Paladin Labs Inc. (CC:PLB) and Somaxon Pharmaceuticals, Inc. (SOMX) Announce Filing of New Drug Submission for Silenor®

2/23/2012 6:07:32 AM

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor® (doxepin) for the treatment and symptomatic relief of insomnia.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Paladin Labs Inc.

• Somaxon Pharmaceuticals, Inc.

• Clinical - BLA/NDA/ANDA